Europe Cancer Diagnostic Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

May 2017 | 350 pages | ID: E2A4AF4DB6FEN
Data Bridge Market Research

Abstracts

The Europe Cancer Diagnostics Market is accounted to reach USD 13.02 billion by 2024 from USD 5.16 billion in 2016, it is growing at a CAGR of 12.3% in the forecast period 2017 to 2024..

The major factors driving the growth of this market are the rise in the aging population in European countries and government initiatives. These factors increase the demand for cancer diagnostic products.

The key market players for Europe Cancer Diagnostics Market are listed below:

• Siemens Healthcare
• Hologic, Inc,
• Becton,
• Dickinson and Company.
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Roche Diagnostics,
• Abbott Laboratories, Inc.,
• QIAGEN.

The market is further segmented into:

• Type
• Application
• Technology
• End User
• Geography

The Europe cancer diagnostics market is segmented on the basis of technology, application and geography. The Europe cancer diagnostics market is segmented into 2 types- platform based and instrument based. In 2017, the cancer diagnostics instrument based segment is expected to dominate the market with a share of 67.5% and is expected to continue this trend till 2024.

Cancer diagnostics platform based market is segmented into polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), DNA microarrays, flow cytometry and others. Cancer diagnostics instrument based market is segmented into imaging and biopsy. Imaging is further segmented into magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography- computed tomography (PET-CT), mammography and ultrasound.

Based on application, the market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma and others.

Based on geography, the Europe Cancer Diagnostics Market is segmented into 11 geographical regions, such as,

• Germany,
• France,
• United kingdom,
• Italy,
• Spain,
• Russia,
• Turkey
• Belgium,
• Netherlands,
• Switzerland,
• Rest of Europe,

Covered in this report

The report covers the present scenario and the growth prospects of the Europe Cancer Diagnostics Market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Contents

1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF EUROPE CANCER DIAGNOSTICS MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS
  3.1.1. GROWTH OF AGING POPULATION AND RISING PREVALENCE OF CANCER
  3.1.2. GOVERNMENT INITIATIVES FOR FUNDING AND AWARENESS ABOUT CANCER
  3.1.3. KEY PLAYERS FOCUSING ON STRATEGIC DECISIONS TO GAIN MARKET SHARE
  3.1.4. INCREASING PREVELANCE OF CANCER
3.2. RESTRAINTS
  3.2.1. STRINGENT REULATIONS IMPOSED BY INTERNATIONAL AND LOCAL AUTHORITIES
  3.2.2. SHORTAGE OF SKILLED AND TRAINED PROFESSIONALS
3.3. OPPORTUNITIES
  3.3.1. NANOTECHNOLOGY: FORTHCOMING REVOLUTION IN CANCER DIAGNOSIS
  3.3.2. ARTIFICIAL INTELLIGENCE AND THE IMMINENT

HEALTH REVOLUTION

  3.3.3. GROWING MEDICAL TOURISM IN ASIA
3.4. CHALLENGES
  3.4.1. INCREASING RIVALRY AMONG THE COMPETITORS
  3.4.2. POOR ACCESS TO CANCER DETECTION AND HIGH TREATMENT COCTS IN LOWER INCOME COUNTRIES

4. PREMIUM INSIGHTS

5. EXECUTIVE SUMMARY

6. EUROPE CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY

6.1. OVERVIEW
6.2. PLATFORM BASED
  6.2.1. POLYMERASE CHAIN REACTION(PCR)
  6.2.2. IN SITU HYBRIDIZATION (ISH)
  6.2.3. IMMUNOHISTOCHEMISTRY(IHC)
  6.2.4. NEXT GENERATION SEQUENCING (NGS)
  6.2.5. DNA MICROARRAYS
  6.2.6. FLOW CYTOMETRY
6.3. INSTRUMENT BASED
  6.3.1. IMAGING
    6.3.1.1. MAGENTIC RESONANCE IMAGING (MRI)
    6.3.1.2. CT(COMPUTED TOMOGRAPHY)
    6.3.1.3. POSITRON EMISSION TOMOGRAPHY- COMPUTED TOMOGRAPHY (PET-CT)
    6.3.1.4. MAMMOGRAPHY
    6.3.1.5. ULTRASOUND
  6.3.2. BIOPSY

7. EUROPE CANCER DIAGNOSTICS MARKET, BY APPLICATION

7.1. OVERVIEW
7.2. LUNG CANCER
7.3. BREAST CANCER
7.4. COLORECTAL CANCER
7.5. MELANOMA
7.6. OTHERS

8. EUROPE CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY

8.1. OVERVIEW
8.2. EUROPE CANCER DIAGNOSTICS MARKET
  8.2.1. GERMANY CANCER DIAGNOSTICS MARKET
  8.2.2. FRANCE CANCER DIAGNOSTICS MARKET
  8.2.3. U.K. CANCER DIAGNOSTICS MARKET
  8.2.4. ITALY CANCER DIAGNOSTICS MARKET
  8.2.5. SPAIN CANCER DIAGNOSTICS MARKET
  8.2.6. RUSSIA CANCER DIAGNOSTICS MARKET
  8.2.7. TURKEY CANCER DIAGNOSTICS MARKET
  8.2.8. BELGIUM CANCER DIAGNOSTICS MARKET
  8.2.9. NETHERLANDS CANCER DIAGNOSTICS MARKET
  8.2.10. SWITZERLAND CANCER DIAGNOSTICS MARKET
  8.2.11. REST OF EUROPE CANCER DIAGNOSTICS MARKET

9. EUROPE CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

9.1. COMPANY SHARE ANALYSIS: EUROPE CANCER DIAGNOSTICS IMAGING MARKET
9.2. COMPANY SHARE ANALYSIS: EUROPE CANCER DIAGNOSTICS PLATFORM BASED MARKET

10. COMPANY PROFILES

10.1. C. R. BARD, INC.
  10.1.1. COMPANY OVERVIEW
  10.1.2. REVENUE ANALYSIS
  10.1.3. PRODUCT PORTFOLIO
  10.1.4. RECENT DEVELOPMENTS
10.2. ILLUMINA, INC.
  10.2.1. COMPANY OVERVIEW
  10.2.2. REVENUE ANALYSIS
  10.2.3. RECENT DEVELOPMENTS
  10.2.4. PRODUCT PORTFOLIO
10.3. QIAGEN
  10.3.1. COMPANY OVERVIEW
  10.3.2. REVENUE ANALYSIS
  10.3.3. RECENT DEVELOPMENTS
  10.3.4. PRODUCT PORTFOLIO
10.4. ABBOTT
  10.4.1. COMPANY OVERVIEW
  10.4.2. REVENUE ANALYSIS
  10.4.3. RECENT DEVELOPMENTS
  10.4.4. PRODUCT PORTFOLIO
10.5. SIEMENS HEALTHCARE GMBH
  10.5.1. COMPANY OVERVIEW
  10.5.2. REVENUE ANALYSIS
  10.5.3. RECENT DEVELOPMENTS
  10.5.4. PRODUCT PORTFOLIO
10.6. AGILENT TECHNOLOGIES
  10.6.1. COMPANY OVERVIEW
  10.6.2. REVENUE ANALYSIS
  10.6.3. PRODUCT PORTFOLIO
  10.6.4. RECENT DEVELOPMENTS
10.7. THERMO FISHER SCIENTIFIC INC.
  10.7.1. COMPANY OVERVIEW
  10.7.2. REVENUE ANALYSIS
  10.7.3. PRODUCT PORTFOLIO
  10.7.4. RECENT DEVELOPMENTS
10.8. BECTON, DICKINSON AND COMPANY
  10.8.1. COMPANY OVERVIEW
  10.8.2. REVENUE ANALYSIS
  10.8.3. PRODUCT PORTFOLIO
  10.8.4. RECENT DEVELOPMENTS
10.9. GE HEALTHCARE
  10.9.1. COMPANY OVERVIEW
  10.9.2. REVENUE ANALYSIS
  10.9.3. PRODUCT PORTFOLIO
  10.9.4. RECENT DEVELOPMENTS
10.10. F. HOFFMANN-LA ROCHE LTD
  10.10.1. COMPANY OVERVIEW
  10.10.2. REVENUE ANALYSIS
  10.10.3. PRODUCT PORTFOLIO
  10.10.4. RECENT DEVELOPMENTS
10.11. HOLOGIC INC.
  10.11.1. COMPANY OVERVIEW
  10.11.2. REVENUE ANALYSIS
  10.11.3. RECENT DEVELOPMENTS
  10.11.4. PRODUCT PORTFOLIO
10.12. KONINKLIJHE PHILIPS N.V.
  10.12.1. COMPANY OVERVIEW
  10.12.2. REVENUE ANALYSIS
  10.12.3. PRODUCT PORTFOLIO
  10.12.4. RECENT DEVELOPMENTS

11. RELATED REPORTS

List Of Tables

LIST OF TABLES

Table 1 EUROPE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2015 – 2024(USD MILLION)
Table 2 EUROPE CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 3 EUROPE PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 4 EUROPE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 5 EUROPE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
Table 6 EUROPE CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)
Table 7 GERMANY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 8 GERMANY PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 9 GERMANY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 10 GERMANY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
Table 11 GERMANY CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)
Table 12 FRANCE CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 13 FRANCE PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 14 FRANCE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 15 FRANCE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
Table 16 FRANCE CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)
Table 17 U.K.CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 18 U.K. PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 19 U.K. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 20 U.K. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
Table 21 U.K. CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)
Table 22 ITALY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 23 ITALY PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 24 ITALY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 25 ITALY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
Table 26 ITALY CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)
Table 27 SPAIN CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 28 SPAIN PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 29 SPAIN INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 30 SPAIN INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
Table 31 SPAIN CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)
Table 32 RUSSIA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 33 RUSSIA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 34 RUSSIA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 35 RUSSIA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
Table 36 RUSSIA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)
Table 37 TURKEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 38 TURKEY PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 39 TURKEY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 40 TURKEY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
Table 41 TURKEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)
Table 42 BELGIUM CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 43 BELGIUM PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 44 BELGIUM INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 45 BELGIUM INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
Table 46 BELGIUM CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)
Table 47 NETHERLANDSCANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 48 NETHERLANDS PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 49 NETHERLANDS INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 50 NETHERLANDS INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
Table 51 NETHERLANDS CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)
Table 52 SWITZERLAND CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 53 SWITZERLAND PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 54 SWITZERLAND INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 55 SWITZERLAND INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
Table 56 SWITZERLAND CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)
Table 57 REST OF EUROPECANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 58 REST OF EUROPE PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 59 REST OF EUROPE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 60 REST OF EUROPE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
Table 61 REST OF EUROPE CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)

List Of Figures

LIST OF FIGURES

Figure 1 EUROPEAN UNION POPULATION AGES 65 AND ABOVE (% OF TOTAL)
Figure 2 EUROPE CANCER DIAGNOSTICS MARKET SNAPSHOT (2017)
Figure 3 EUROPE CANCER DIAGNOSTICS MARKET, BY COUNTRY (2016)
Figure 4 EUROPE CANCER DIAGNOSTICS MARKET BY COUNTRY (2017)
Figure 5 EUROPE CANCER DIAGNOSTICS MARKET BY COUNTRY (2016 & 2024)
Figure 6 EUROPE CANCER DIAGNOSTICS MARKET BY TECHNOLOGY (2017 & 2024)